The trial "worked" —
so why did nothing change?

Before — only the company's version

Companies disclosed rejection reasons themselves. Sensitive issues like safety signals, data gaps or manufacturing problems could be softened or left out, so investors and patients rarely knew the real reason.

After — the FDA's letter itself

The FDA publishes the letter (with confidential details removed). What data fell short and which safety signals mattered become visible, companies find it harder to spin the rejection, and everyone gets the same information.

Biogen's Tau Drug diranersen Heads to Phase 3 Despite Missing Its Primary Endpoint

BioSpace · Investing.com · Biogen (NASDAQ: BIIB) | AAIC 2026 · Jul 14, 2026

Key Facts

Phase 2 data presented by Biogen at AAIC 2026 in London showed its tau-targeting drug diranersen reduced toxic tau tangles in the brain by 50–65%. But the primary endpoint, which measured cognitive improvement, did not reach statistical significance. Biogen still decided to move into Phase 3, pointing to positive signals across secondary measures and the biological meaning of tau reduction. Existing Alzheimer's drugs like Leqembi clear amyloid plaques; diranersen goes after the tau tangles that actually kill brain cells, a more upstream approach.

Plain-English Breakdown 🧩

An Alzheimer's brain has two protein problems: amyloid plaques that build up outside cells, and tau that tangles inside them. Existing drugs clean up the plaques, but it's the tau that kills neurons, and diranersen attacks it directly. It missed the primary endpoint, but cutting tau by more than half is still real scientific evidence, and Biogen and the market read it as progress rather than failure.

📌 Biogen's tau drug missed its primary endpoint but went straight to Phase 3 — a clinical miss and scientific progress aren't always the same thing. — BioSpace / AAIC 2026 summary

The FDA Resumes Publishing Complete Response Letters, Exposing What Companies Kept Quiet

Fierce Biotech · FDA | Jul 14, 2026

Key Facts

The FDA resumed its policy of publishing complete response letters (CRLs), which it had paused in April 2026 after legal pushback. A CRL is the formal letter explaining why a drug application was rejected — safety concerns, missing data, manufacturing defects and so on. Until now these were confidential, and companies could frame their disclosures favourably ("we plan to submit additional data"). Under the policy, investors, patients and competitors can read the FDA's own words, making it much harder to spin a rejection, which could mean bigger share drops and more securities litigation risk.

Plain-English Breakdown 🧩

When a drug was rejected, companies typically said something like "we plan to resubmit with additional data," and the specific reasons stayed hidden. Now the FDA publishes the letter itself. Same exam score, but now everyone can see which questions you got wrong and why. For companies, it's a far more transparent and far less comfortable world.

📌 The FDA is publishing rejection letters again — when a company gets a CRL, investors and patients will see the reasons. The balance of information is shifting. — Fierce Biotech summary

IQVIA Data Confirms Foundayo's Slow Start: Formularies, Not Science, Decide the Market

Fierce Pharma · IQVIA data · Eli Lilly (NYSE: LLY) | Jul 17, 2026

Key Facts

Real-world prescription tracking from IQVIA shows Lilly's oral obesity drug Foundayo trailing its competitor badly in early prescriptions. The main reason isn't efficacy but delays in getting onto the big PBMs' formularies. Injectable GLP-1s (Ozempic, Wegovy, Zepbound) already have established coverage, while Foundayo, as a new oral molecule, has to negotiate its own way on. It's another example of US obesity market share depending on PBM negotiations more than trial data.

Plain-English Breakdown 🧩

IQVIA tracks actual pharmacy prescriptions, and investors use it to judge launches: FDA approval → IQVIA scripts → sales forecasts. Low Foundayo numbers mean prescriptions aren't reaching pharmacies, because without PBM coverage, insurance won't pay, so patients and doctors hold back. Even the best drug can't reach the pharmacy counter if it loses at the pricing table.

📌 IQVIA prescription data confirms Foundayo's slow start — in the US obesity market, the winner isn't the best science but whoever wins the PBM negotiation. — Fierce Pharma summary

🔎 Why this pattern

This week the market read the context, not the headline. Biogen rose despite a missed primary endpoint, while Lilly fell despite having an approved drug, because of what IQVIA data showed. The stock moves showed how much it matters to read clinical science and market data together. (All directional sketches — check a real chart for exact prices.)

🎯 Roles to Watch This Week

Teams worth watching based on this issue's news — not live job postings, so check each company's careers page for what's actually open.